Obiectivele studiului sunt urmarirea eficacitatii, sigurantei si tolerabilitatii administrarii de ruxolitinib fata de cea mai buna terapie disponibila la pacientii cu boala grefa contra gazda.

Titlu Studiu

A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)

Cod protocol: CINC424D2301

Numar EudraCT: 2016-005020-29

Sponsor: Incyte Corporation

Medicament de investigatie clinica: Ruxolitinib

Medicament de investigatie clinica comparator: metotrexat, micofenolat, everolimus, sirolimus, infliximab, rituximab, pentostatin, imatibinib, ibrutinib,

Placebo: nu

International/National: international

Faza: III

Centre România

Novartis Investigational Site, Bucuresti, Romania, 022328